CAS 1025821-33-3

Formula: C18H10Cl2N4OS

InChI: InChI=1S/C18H10Cl2N4OS/c19-11-2-1-3-12(20)16(11)23-18-24-17(25)15(26-18)9-10-4-5-13-14(8-10)22-7-6-21-13/h1-9H,(H,23,24,25)/b15-9-

InChI key: RJPNRXFBYZVRIB-DHDCSXOGSA-N

SMILES: C1=CC(=C(C(=C1)Cl)N=C2NC(=O)/C(=C/C3=CC4=NC=CN=C4C=C3)/S2)Cl

GSK-626616

CAS: 1025821-33-3

GSK-626616: strong, oral DYRK3 inhibitor (IC50: 0.7 nM), affects DYRK family, may treat anemia.

Formula: C₁₈H₁₀Cl₂N₄OS

Purity: 98.27%

Color and Shape: Solid

Molecular weight: 401.269

Ref: TM-T15422

GSK-626616

CAS: 1025821-33-3

GSK-626616

Formula: C₁₈H₁₀Cl₂N₄OS

Purity: ≥98%

Molecular weight: 401.27

Ref: 54-BUP04439

(5Z)-2-[(2,6-Dichlorophenyl)amino]-5-(6-quinoxalinylmethylene)-4(5H)-thiazolone

CAS: 1025821-33-3

Formula: C₁₈H₁₀Cl₂N₄OS

Purity: 98%

Color and Shape: Solid

Molecular weight: 401.2692

Ref: IN-DA01ENHC

GSK 626616

CAS: 1025821-33-3

Potent inhibitor of dual specificity tyrosine-phosphorylation-regulated kinase 3 (DYRK3) with IC50 value of 0.7 nM. Elevates hemoglobin and platelet levels in anemic mice.

Formula: C₁₈H₁₀Cl₂N₄OS

Purity: Min. 98 Area-%

Color and Shape: Powder

Molecular weight: 401.27 g/mol

Ref: 3D-BG166664

GSK 626616 - Bio-X ™

CAS: 1025821-33-3

This product is part of our Bio-X ™ Range. These products are aimed at life science researchers who need high quality ready-to-use products for assay development, screening or other R&D work. With a solubility datasheet and convenient vials, all of our Bio-X ™ products are in stock across our global warehouses for rapid delivery and ease of use.

Formula: C₁₈H₁₀Cl₂N₄OS

Purity: Min. 95%

Color and Shape: Powder

Molecular weight: 401.27 g/mol

Ref: 3D-BG300011

GSK-626616

CAS: 1025821-33-3

(Z)-2-((2,6-Dichlorophenyl)amino)-5-(quinoxalin-6-ylmethylene)thiazol-4(5H)-one

Formula: C₁₈H₁₀Cl₂N₄OS

Purity: 99%

Molecular weight: 401.27

Ref: IN-DG00817544

GSK-626616

Controlled Product

CAS: 1025821-33-3

Applications GSK-626616 is a potent and selective DYRK inhibitor (IC50 = 0.7 nM for DYRK3, similar potency for DYRK1 and 2). Exhibits ~20-fold selectivity over casein kinase 2 and negligible activity against a panel of 451 kinases screened. Enhances number of CFU-E stimulated by Epo from human marrow. Increases hemoglobin levels in anemic mice. Orally bioavailable.
References Wippich, Frank., et al.: Cell., 152, 791(2013); Corona, John A., et al.: Org. Process Res. Dev., 14, 712 (2010)

Formula: C₁₈H₁₀Cl₂N₄OS

Color and Shape: Neat

Molecular weight: 401.27

Ref: TR-G797853